A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

NCT03023423 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Atezolizumab
DRUG: Daratumumab

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]